One method is one opinion
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Integration
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
The threshold is the parameter with the largest effect. Below it a feature is treated as noise and does not enter the calculation; above it, it becomes an impurity subtracting from the reported purity. A threshold at a tenth of one per cent of the main peak area discards a population of small related species that a threshold at two-hundredths of a per cent would report individually. Both settings are defensible for their purposes. Only one of them is capable of producing a purity figure below 99 on a well-made peptide, which is a fact about the parameter rather than about the powder.
Under a tailing peak, the area depends on where the baseline is drawn, and the software offers several conventions — a straight line between valley points, an exponential skim, a tangential skim for a shoulder. For a symmetrical peak on a flat baseline the differences are trivial. For a small impurity riding on the tail of a large parent they are not, and they are the commonest genuine disagreement between two competent analysts looking at the same trace.
The denominator is decided by the solvent-front convention. Everything eluting in the first moments of a gradient run — unretained salts, injection solvent, dissolved gases, mobile-phase impurities — is conventionally excluded, and rightly so. Methods differ on where the exclusion window ends, and the choice determines whether an early-eluting hydrophilic fragment is an impurity or a non-event. The difference between a window closing at one and a quarter minutes and one closing at two and a half is not analytical laxity; it is a judgement about the separation, and it moves the number.
Manual reintegration deserves a word, because it has an undeserved reputation. Reintegrating by hand is entirely legitimate — software misassigns peak boundaries regularly — and in regulated practice it is permitted, documented and audited, with the original and revised integrations retained. What is not acceptable is undeclared reintegration, and in this market there is no mechanism by which it would ever be declared.1
Regulated pharmaceutical practice does not treat all small peaks alike. It defines three thresholds. A reporting threshold is the level above which an impurity must be listed in the results. An identification threshold is the level above which its structure must be established. A qualification threshold is the level above which its biological safety must be addressed. The three are set by dose and product class, and the framework converts an argument about small peaks into a documented decision procedure.
The trade has no equivalent. There is no reporting threshold, so an impurity is listed or not according to the software settings; no identification threshold, so nothing is ever identified; and no qualification threshold, because there is no regulatory obligation to qualify anything in a research chemical. The practical consequence is that a certificate reporting 98.6 per cent purity conveys nothing about whether the missing 1.4 per cent is thirty innocuous deletion sequences or one substantial unidentified species.
This is the gap the Journal would most like to see narrowed, and it can be narrowed cheaply. Listing the three largest impurities with their relative retention times and areas costs nothing, requires no additional analysis, and transforms the informational content of the document. One of the twenty companies we track does it. It is not a coincidence that the same company answered every question we put to it about its analytical methods.2
A method reading at 280 nanometres cannot see a fragment that has lost its aromatic residue, however much of it is there.
On detection wavelengthThe Journal buys material and has it tested, and the design of those exercises deserves the same disclosure we ask of others. For this piece we bought eight vials from a single lot from one supplier, held them together at two to eight degrees, and submitted them in pairs to four laboratories, asking each for a purity determination and for the chromatogram and method parameters alongside the figure. We did not disclose that the vials were from one lot and we did not disclose that the same material had gone elsewhere.
Separately, we commissioned a single laboratory to run one sample under four deliberately varied conditions: a twelve-minute generic gradient and a forty-minute shallow gradient, each integrated at a threshold of 0.1 per cent and 0.05 per cent. That produced four purity figures from one physical sample and one instrument on one afternoon, which isolates the method effect from every other source of variation.
The limitations are ours to state. One lot from one supplier is not a survey of the market. Single injections carry the variability of single injections. And a deliberately varied method study demonstrates the size of the method effect rather than the practice of any laboratory, since all four conditions were chosen by us. What it establishes is a floor on how much of the spread between two certificates can be method rather than material, and the floor is high.3
| Wavelength | Principal absorber | Sees fragments without aromatics | Baseline noise | Typical use |
|---|---|---|---|---|
| 214 nm | Amide bond | Yes | Higher | Peptide purity and related substances |
| 220 nm | Amide bond | Yes | Moderate | Peptide purity, quieter baseline |
| 254 nm | Aromatic systems | No | Low | Small-molecule work, legacy detectors |
| 280 nm | Trp, Tyr, Phe side chains | No | Low | Tracking an aromatic residue; not a purity method |
| Diode array, 200–400 nm | All of the above | Yes | Method-dependent | Peak purity assessment, spectral homogeneity |
| A purity figure generated at 280 nm is not comparable with one generated at 214 nm, and the difference is not a matter of a percentage point. Certificates reading at 280 nm circulate in this market; readers have sent us several. | ||||
Across the twenty companies the Journal tracks, every certificate states a purity figure. Rather fewer state the method in any form. A minority name the detection wavelength. Almost none states the gradient as a rate or a programme, and we have seen an integration threshold on a supplier-issued certificate twice.
Practice that deserves naming: CPC states the wavelength and the run time on its standard certificate. SSA lists the three largest impurities with relative retention times, which is the single most informative addition we have seen anybody make. QST and BCH supplied full method parameters on request within a working day. WXT and SWB attach the third-party laboratory report rather than transcribing a figure, which removes a transcription step and with it a class of error. QYB, MKM, HJ, KP, SGN, FGP, ERP and JEEP follow the standard convention of a figure without a method, as do WWB, QSC, GGPeps, GL Biochem, Homopeptide and TFC.
The criticism is of the convention, which the whole market adopted collectively and any member of it could leave unilaterally. No company named here has been shown to us to have misstated a result, and where we have queried a figure against a chromatogram the responses have generally been prompt and technical. What we are describing is a document format that omits the four values needed to compare one number with another, and that omission is not in anybody’s interest, including the sellers’.
A peptide in a vial exists in whatever state the manufacturer left it. Reconstituted in water, a hydrophobic sequence may not dissolve completely and the chromatogram will show particles or aggregates. Reconstituted in an acidic buffer, the same sequence dissolves and the chromatogram shows monomer. The purity figure—and the mass balance—changes accordingly. Sample preparation is not one of the twelve values that belong on a method disclosure, and yet it is one of the most consequential, because it determines what population the peptide is actually in when the injection happens.4
The trade addresses this by assuming that samples are dissolved in the mobile phase or its aqueous component, and the assumption is sometimes true and sometimes false. A certificate that states how the sample was dissolved, at what concentration, in what solvent and after what incubation time, is one that can be repeated. A certificate that does not is one that will produce different results if the receiving laboratory uses different dissolution practice, which is particularly consequential for poorly soluble sequences.
The technique is not on trial here and never was. Reversed-phase chromatography can resolve species differing by a single methyl group, and the laboratories running it for this market are, on the evidence we have gathered, largely competent and entirely willing to describe what they did when somebody asks. What is on trial is a document format that omits the four values needed to compare one figure with another.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
On the section about diode-array detection and peak purity, I would add that true peak purity assessment requires library matching or at least spectral comparison across the peak width. A homogeneous spectrum tells you the peak is probably pure. A spectrum that shifts across the peak tells you it is not, and that information closes a gap the article identifies correctly.
— P. Kovalenko, Lviv
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
We set out the parameters a method disclosure would contain, all of which are known to whoever ran the sample and none of which is commercially sensitive.
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
A reminder that a purity figure is the output of a method, and that methods differ.